What Endpoints News does

Endpoints News is an independent B2B media organization that analyzes and reports on global biotech and pharmaceutical R&D, with editorial focus on the science, people, and money driving the industry. Founded in 2016 by Arsalan Arif and John Carroll in Lawrence, Kansas, the company was bootstrapped without external investors and achieved profitability from inception under an unconventional 50/50 co-founder ownership structure. The Financial Times acquired Endpoints News in 2023, allowing the editorial team to continue operating independently under the FT Specialist umbrella. Headcount is 51-100 employees, and the company marked its 10th anniversary in 2026.

The platform is organized around a core digital news site (endpoints.news) supplemented by 11 specialized Topic Hubs (covering AI drug discovery, antibody-drug conjugates, biopharma M&A, China biotech, CRISPR, GLP-1 drugs, IRA drug pricing, and others) and 26+ content Channels (including FDA+, Bioregnum, Biotech Voices, Cell/Gene Tx, Nikkei Biotechnology, Peer Review). Proprietary products include the BioPharma Sentiment Index (BPSI), a quarterly sentiment survey with 1,457 verified industry respondents in Q4 2025; the IPO Tracker for biotech public offerings; the Signal newsletter and market analysis channel; the Endpoints 100 CEO survey; Endpoints Webinars; and Biopharma Jobs, a specialized recruitment portal.

Revenue is generated through a diversified B2B media monetization model: advertising and sponsored content sold through Endpoints Studio, webinar and event hosting, recruitment advertising on Biopharma Jobs, and merchandise sales. Endpoints serves three primary customer segments — biopharmaceutical R&D and business development professionals, biotech-focused investors and fund managers, and regulatory affairs personnel — across a horizontal segmentation of the biopharma value chain. The publication provides specialized intelligence on R&D, deal-making, financing, IPO activity, and regulatory developments that generalist business news does not cover with equivalent depth.

Name

Endpoints News

Legal name

Endpoints News

Website

https://endpts.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Endpoints News is an independent B2B media outlet covering global biotech and pharmaceutical R&D. Founded in 2016 and acquired by the Financial Times in 2023, it serves biopharma professionals, investors, and regulatory specialists with news, proprietary sentiment surveys, IPO tracking, webinars, and topic-specific coverage hubs.

Ownership category

akta.pro rank

Product category

Biopharma Trade Media

NAICS

Newspaper, Periodical, Book, and Directory Publishers (5131), Periodical Publishers (51312)

SIC

Newspapers: Publishing Or Publishing & Printing (2711)

akta.pro primary industry

Business, Financial & Trade News Publishers (MPAJADAC)

Keywords

• Biotech news reporting
• Pharmaceutical industry journalism
• Biopharma market intelligence
• Industry sentiment analysis
• Biotech media platform

Headquarters

HQ city

Lawrence

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Advertising and Sponsorships: Endpoints News generates revenue through sponsored posts and advertising services offered via Endpoints Studio. The platform provides advertising opportunities to biopharma companies and related businesses seeking to reach the outlet's industry audience.
2. Webinars and Events: The company operates webinars.endpoints.news and hosts events through endpoints.studio/events, providing virtual and in-person industry event content for revenue generation.
3. Job Board: Biopharma Jobs platform (careers.endpoints.news) and job listings via the Work at Endpoints careers page, enabling recruitment advertising to the biotech/pharma audience.
4. Merchandise: Endpoints branded merchandise sold through store.endpts.com.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Endpoints News is an independent digital media platform that publishes specialized biotech and pharmaceutical business news coverage focused on science, people, and money driving the biopharma industry. The company distributes editorial content through its website organized into specialty channels and topic hubs, supported by proprietary analytical tools including the Biopharma Sentiment Index (BPSI), an IPO Tracker, the Signal newsletter, webinars, a CEO survey, and a biopharma job board. Revenue is generated through advertising, sponsored posts, events, recruitment listings, and merchandise.

Product overview

Endpoints News is a biotech and pharma business news platform organized around a core news site supplemented by specialized Topic Hubs covering 11 key industry areas, including AI drug discovery, ADCs, GLP-1 drugs, CRISPR, and China biotech. The publication offers several integrated products: Signal (newsletter and analysis channel), the Biopharma Sentiment Index (BPSI) quarterly survey product, an IPO Tracker for market monitoring, Endpoints Webinars for live events, the Endpoints 100 CEO survey for industry research, and a Biopharma Jobs career portal. The company was acquired by the Financial Times in 2023 and operates with continued editorial independence.

Differentiator

Problem solved

Functional benefit

Brands

• Signal: A channel/product focused on biotech market insights and sentiment analysis, including the Biopharma Sentiment Index.
• Endpoints Webinars
• Biopharma Sentiment Index (BPSI)
• IPO Tracker

Products and services

• Endpoints News Platform Core digital news platform delivering specialized biotech and pharmaceutical business news coverage of science, people, and money through real-time articles, exclusive stories, and 28 specialty reporting channels for biopharma professionals.
• Signal Specialized newsletter channel offering biotech stock market insights, industry trend analysis, and Biopharma Sentiment Index (BPSI) survey results for biopharma executives and investors.
• Biopharma Sentiment Index (BPSI) Quarterly sentiment survey measuring mood within the biopharmaceutical industry among verified industry stakeholders (1,457 respondents in Q4 2025), tracking optimism and outlook on funding, deal-making, and market conditions.
• IPO Tracker Market tracking tool monitoring biotech IPO activity and offering visibility into new public offerings and conditions in the biotech IPO market.
• Endpoints Webinars Webinar platform hosting live and on-demand educational events, interviews, and panel discussions covering biopharma industry topics.
• Endpoints 100 Survey Periodic CEO survey gathering predictions and insights from biotech executives on industry trends, regulatory matters such as MFN pricing, and FDA policy recommendations.
• Biopharma Jobs Specialized job board connecting professionals with career opportunities across the biopharmaceutical industry, with recruitment advertising sold to biotech and pharma employers.

Quantifiable outcome

• BioPharma Sentiment Index climbed to 96 in Q2 2026 from 78 in Q4 2025, approaching neutral territory for first time since post-pandemic downturn
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Biopharma Dive: Biopharma Dive is a trade news outlet covering biopharma business, R&D, and policy, owned by Informa. It competes for the same executive readership and ad/sponsorship budgets in biopharma.
• BioSpace: BioSpace combines biopharma industry news with a substantial job board and career marketplace. It overlaps with Endpoints across news, deals, and the careers/jobs vertical, and serves the same biopharma professional audience.
• Fierce Biotech: Fierce Biotech is a long-standing trade publication covering biotech R&D, FDA news, and industry deals, owned by Informa. It overlaps directly with Endpoints' R&D, FDA, and Deals channels and competes for the same advertising dollars.
• Drug Discovery & Development: Drug Discovery & Development covers pharma R&D, pipelines, and discovery technology for industry scientists and business leaders — a comparable trade publication with overlapping R&D and pipeline coverage.
• BioCentury: BioCentury is a subscription-based biopharma intelligence publication focused on R&D strategy, deal-making, and policy — a comparable vertical-specialty model with overlapping readership in biotech business development and investing.
• STAT News: STAT is the most direct competitor in biopharma and life-sciences journalism, covering R&D, deals, and policy for a similar professional audience. Both compete for biopharma executives' attention and for the same pool of advertisers and sponsors.
• Genetic Engineering & Biotechnology News (GEN): GEN is a long-running trade publication covering biotech R&D, discovery, and manufacturing — comparable in editorial coverage to Endpoints' Discovery and Cell/Gene Tx channels for a biopharma R&D audience.
• Pink Sheet / Citeline: Pink Sheet and Citeline (Informa) provide deep regulatory, policy, and pipeline intelligence for biopharma. They overlap with Endpoints' FDA+ channel and regulatory affairs coverage for a similar professional audience.

Broad incumbents

• Bloomberg Industry (Pharma & Biotech coverage): Bloomberg provides broad financial and industry news including substantial biopharma coverage, but as part of a much wider portfolio. It competes with Endpoints for biopharma executive mindshare and for ad/sponsorship dollars from large pharma advertisers.
• Reuters Health: Reuters covers pharma and biotech news as part of its global generalist newsroom. It does not specialize in biopharma but competes for breaking-news attention and overlaps in coverage of FDA actions, M&A, and drug-pricing policy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/endpts
• LinkedInlinkedin.com/company/endpoints
• Facebookfacebook.com/endpoints

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endpoints News